LocanaBio
Main focus: Next-generation editing of RNA to treat genetic diseases
Company stage: Pre-clinical
Diseases: amyotrophic lateral sclerosis (ALS), myotonic dystrophy type 1 (DM1), Huntingtons disease, retinal diseases
Genome editing tool: CRISPR-Cas13d
Funding stage: Private
Location: San Diego, CA, USA
Website: https://locanabio.com/
Pipeline: https://locanabio.com/pipeline/
LocanaBio is developing next-generation RNA-editing technologies, applying its proprietary CRISPR-based CORRECTX™ platform to do so. The company focuses on neuromuscular, neurodegenerative and ophthalmologic diseases, with multiple pre-clinical programmes currently under development.